138 related articles for article (PubMed ID: 11592534)
1. Influence of topical brimonidine on visual field in glaucoma.
Ruiz Lapuente C; Ruiz Lapuente A; Link B
Eur J Ophthalmol; 2001; 11 Suppl 2():S67-71. PubMed ID: 11592534
[TBL] [Abstract][Full Text] [Related]
2. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
[TBL] [Abstract][Full Text] [Related]
3. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.
Mastropasqua L; Ciancaglini M; Carpineto P; Zuppardi E; Falconio G; Gallenga PE
Acta Ophthalmol Scand Suppl; 1998; (227):36. PubMed ID: 9972338
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L
Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124
[No Abstract] [Full Text] [Related]
6. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
7. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
[TBL] [Abstract][Full Text] [Related]
8. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies.
Merin S; Obolensky A; Farber MD; Chowers I
J Ocul Pharmacol Ther; 2008 Feb; 24(1):80-6. PubMed ID: 18201138
[TBL] [Abstract][Full Text] [Related]
10. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
11. Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma.
Feke GT; Bex PJ; Taylor CP; Rhee DJ; Turalba AV; Chen TC; Wand M; Pasquale LR
Am J Ophthalmol; 2014 Jul; 158(1):105-112.e1. PubMed ID: 24709811
[TBL] [Abstract][Full Text] [Related]
12. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
13. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
15. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
17. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure.
Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC; Seah SK; Chew PT
Br J Ophthalmol; 2004 Jan; 88(1):88-94. PubMed ID: 14693782
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Barnebey HS; Robin AL; Zimmerman TJ; Morrison JC; Hersh SB; Lewis RA; Coleman AL; Cinotti DJ; Walt J; Chen KS
Ophthalmology; 1993 Jul; 100(7):1083-8. PubMed ID: 8100625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
